Cannabinoids produce biochemical and pharmacological results by interacting with the central cannabinoid (CB1) and peripheral cannabinoid (CB2) G protein-coupled receptors. AM630 is a selective CB2 receptor antagonist that binds to CB1 and CB2 receptors with Oki values of 5.2 µM and 31.2 nM, respectively.1 AM630 behaves as an inverse agonist at CB2 receptors, attenuating the antinociceptive results of plenty of cannabinoids, and as a weak partial agonist at CB1 receptors. 1,2,3.
Chemical and bodily information
Molar mass 504.360 g/mol